Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CXCL5 / LIX drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Human) | Recombinant Human CXCL5 Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View CXCL5 Products |
| Antigen (Mouse Homolog) | Recombinant Mouse LIX / CXCL5 Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View LIX Products |
| Gene Delivery (Receptor) | CXCR2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction (Flow Cytometry/Calcium Flux). |
View CXCR2 Products |
| Benchmark Ab | Anti-CXCL5 Recombinant Antibody Recombinant positive control for neutralization and ELISA assays. |
View CXCL5 Products |
| Validator | CXCL5 siRNA Set For knockdown verification in functional cell assays. |
View CXCL5 Products |
| Related Target A | CXCR2 The primary G-protein coupled receptor for CXCL5/LIX mediating chemotaxis. |
View CXCR2 Products |
| Related Target B | CXCL8 / IL-8 Synergistic CXCR2 ligand; critical for selectivity and cross-reactivity profiling. |
View CXCL8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species translation (Human vs. Mouse LIX) | Highly pure Human CXCL5 and Mouse LIX/CXCL5 ortholog proteins available (>95% purity) |
| Receptor activation background noise | Endotoxin-controlled (<1.0 EU/μg) and HEK293-expressed native glycosylation |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CXCL5 / LIX R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The CXCL5/LIX-CXCR2 signaling axis is a critical driver of neutrophil recruitment, angiogenesis, and tumor microenvironment (TME) immunosuppression. The race for CXCL5 therapeutics is intensifying, with major players shifting focus from traditional mAbs to combination therapies targeting the myeloid-derived suppressor cell (MDSC) axis. As first-generation CXCR2 small molecule antagonists face tolerability challenges, the next wave of R&D is targeting ligand-specific neutralization via high-affinity monoclonal antibodies and bispecific biologics to avoid systemic toxicity while preserving localized efficacy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Academic & Biotech Consortia | COPD, Rheumatoid Arthritis | Neutralization Assay (Need endotoxin-controlled, bioactive-compatible CXCL5) |
| Bispecific Antibody | Oncology Biotechs | Solid Tumors (NSCLC, Prostate) | Selectivity Assay (Need CXCL5 vs CXCL8/IL-8 cross-screening panels) |
| Small Molecule (CXCR2) | AstraZeneca, Dompé | Inflammatory Diseases, Cancer | Cell-based Receptor Activation (Need Lentivirus for CXCR2 stable cell lines) |